PerspectiveType 1 Diabetes

Humanizing Animal Models: A Key to Autoimmune Diabetes Treatment

See allHide authors and affiliations

Science Translational Medicine  02 Feb 2011:
Vol. 3, Issue 68, pp. 68ps4
DOI: 10.1126/scitranslmed.3002102

You are currently viewing the abstract.

View Full Text


Preclinical evaluation of antibody-based immunotherapies for the treatment of type 1 diabetes (T1D) in animal models is often hampered by the fact that the human antibody drug does not cross-react with its mouse counterpart. In this issue of Science Translational Medicine, researchers describe a new mouse model that expresses the human isoform of a molecule targeted by T1D antibody therapies that are currently being tested in clinical trials—the human epsilon chain of the CD3 complex expressed on T cells. Anti-CD3 is capable of reducing insulin needs in individuals with recently diagnosed T1D; however, the precise underlying mechanisms of action and the minimal effective dose have been difficult to define. The new humanized mouse model will be instrumental in optimizing anti-CD3–based therapies and accelerating their clinical realization.


  • Citation: D. Bresson, M. von Herrath, Humanizing Animal Models: A Key to Autoimmune Diabetes Treatment. Sci. Transl. Med. 3, 68ps4 (2011).

View Full Text